Working
Groups
This Action brought together Chronic GvHD (cGvHD) researchers across Europe for the first time, creating a network of cross-disciplinary experts in the field.
Working Group 1
Epidemiology
Lead
Daniel Wolff
Country
Germany
daniel.wolff@ukr.de
Vice Lead
Drazen Pulanic
Dr Pulanic is a specialist of Internal Medicine and Subspecialist in Hematology in the department of Internal Medicine, University Hospital Center Zagreb and Medical School University of Zagreb, Croatia.
Drazen Pulanic
Country
Croatia
dpulanic@yahoo.com
Overview
The development of an epidemiological platform on cGvHD within EUROGRAFT was a novel approach to understanding the disease incidence and associated comorbidities.
Results and publications
The epidemiology working group reported on incidence of cGvHD across transplant centres in Europe Training School, “Epidemiology and epigenetics of cGvHD”.
It also produced two important scientific articles, published in Bone Marrow Transplantation.
Follow the links to find the publications of Vladimir Perovic et al (2022) and Ana Zelic Kerep et al (2023).
Other working groups
Biomarkers
This Working Group will assess the type and amount of biomarker information which is currently available in the literature and assess those which are worthy of further validation and study.
Socioeconomics/Quality of life
CGvHD is a long term complex disease which has several co-morbidities and as such impacts on the quality of life of patients. By studying the societal impact of the disease via documented quality of life assessments, including reduced working days due to hospital stays, EUROGRAFT will allow an improved assessment of the burden on society of cGvHD at both the individual and European level.
NIH Consensus
The NIH consensus criteria needs to be implemented uniformly if diagnosis and treatment of
cGVHD is to be optimized. The aim of this Working Group will be to aid in both the understanding and
implementation of the NIH Consensus via Training Schools and workshops.
